| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,000 | 0,000 | 08:00 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.10. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 17.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 17.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 17.10.2024ISIN NameCA0403282050 ARHT... ► Artikel lesen | |
| 07.10. | Arht Media Inc (2): Arht Media downgraded to NEX | ||
| 04.10. | Arht Media Inc (2): Arht Media to remain halted | ||
| 04.10. | ARHT Media files for bankruptcy | ||
| 04.10. | Arht Media Latest Small Cap Firm To File For Bankruptcy |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15.11. | BIORA THERAPEUTICS, INC. - 8-K, Current Report | ||
| 14.11. | Biora Therapeutics GAAP EPS of -$5.04 misses by $1.19, revenue of $0.03M | ||
| 14.11. | Progenity Inc Stock Hits 52-Week Low at $2.37 Amid Sharp Decline | ||
| 14.11. | Biora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results | Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance... ► Artikel lesen | |
| 13.11. | Biora Therapeutics' Earnings Outlook |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | S&W Seed Co reports results for the quarter ended September 30 - Earnings Summary | ||
| 26.11. | S&W Seed GAAP EPS of -$7.17, revenue of $8.3M | ||
| 26.11. | S&W Seed Company: S&W Files First Quarter 2025 10-Q | LONGMONT, Colo., Nov. 26, 2024 /PRNewswire/ -- S&W Seed Company (Nasdaq: SANW) today announced it has filed its 10-Q for the three months ended September 30... ► Artikel lesen | |
| 26.11. | S&W Seed Co - 8-K, Current Report | ||
| 26.11. | S&W Seed Co - 10-Q, Quarterly Report |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15:26 | Sadot Group Inc. Completes Strategic $3.0 Million Capital Raise | BURLESON, TX / ACCESSWIRE / December 3, 2024 / Sadot Group Inc. (NASDAQ:SDOT) ("Sadot" or the "Company"), today announced the pricing of a strategic $3.0 million capital raise through a convertible... ► Artikel lesen | |
| 20.11. | Sadot Group (SDOT) Stock Is Up 16% Today: What's Going On? | ||
| 13.11. | Sadot Group Inc. - 8-K, Current Report | ||
| 13.11. | Sadot Group Inc reports results for the quarter ended September 30 - Earnings Summary | ||
| 12.11. | Sadot Group GAAP EPS of $0.23 misses by $0.37, revenue of $201.7M beats by $27.69M |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | StrikePoint Gold Inc.: StrikePoint Closes Upsized Second and Final Tranche of Private Placement | Vancouver, British Columbia--(Newsfile Corp. - November 27, 2024) - StrikePoint Gold Inc. (TSXV: SKP) (OTCQB: STKXF) ("StrikePoint" or the "Company") is pleased to announce that it has closed the second... ► Artikel lesen | |
| 13.11. | StrikePoint Gold extends private placement | ||
| 13.11. | Strikepoint Gold Inc (3): Strikepoint Gold extends $3-million financing | ||
| 13.11. | StrikePoint Gold Inc.: Strikepoint Announces Extension of Private Placement | Vancouver, British Columbia--(Newsfile Corp. - November 13, 2024) - StrikePoint Gold Inc. (TSXV: SKP) (OTCQB: STKXF) ("StrikePoint" or the "Company") announces that further to its news releases dated... ► Artikel lesen | |
| 08.11. | Strikepoint Gold Inc (3): Strikepoint Gold closes $1.65M 1st financing tranche |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.11. | TuHURA gears up for Phase 3 cancer trial in 2025 | ||
| 25.11. | TuHURA bereitet sich auf Phase-3-Krebsstudie im Jahr 2025 vor | ||
| 25.11. | TuHURA Biosciences, Inc. Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update | IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma (MCC)... ► Artikel lesen | |
| 25.11. | TuHURA Biosciences, Inc./NV - 8-K, Current Report | ||
| 15.11. | TuHURA Biosciences, Inc./NV - 8-K, Current Report |
| Unternehmen / Aktien | Kurs | % |
|---|---|---|
| ARHT MEDIA INC | 0,008 | -100,00 % |
| BIORA THERAPEUTICS INC | 1,940 | -3,00 % |
| S&W SEED COMPANY | 6,910 | +5,50 % |
| SADOT GROUP INC | 4,000 | -7,41 % |
| STRIKEPOINT GOLD INC | 0,121 | -0,41 % |
| TUHURA BIOSCIENCES INC | 5,400 | +1,89 % |
